162 related articles for article (PubMed ID: 19880675)
1. A randomized, placebo-controlled study of the effects of the p38 MAPK inhibitor SB-681323 on blood biomarkers of inflammation in COPD patients.
Singh D; Smyth L; Borrill Z; Sweeney L; Tal-Singer R
J Clin Pharmacol; 2010 Jan; 50(1):94-100. PubMed ID: 19880675
[TBL] [Abstract][Full Text] [Related]
2. In vitro modeling of COPD inflammation and limitation of p38 inhibitor - SB203580.
Meng A; Zhang X; Wu S; Wu M; Li J; Yan X; Kopec-Harding K; Wu J
Int J Chron Obstruct Pulmon Dis; 2016; 11():909-17. PubMed ID: 27199554
[TBL] [Abstract][Full Text] [Related]
3. Synergistic effects of p38 mitogen-activated protein kinase inhibition with a corticosteroid in alveolar macrophages from patients with chronic obstructive pulmonary disease.
Armstrong J; Harbron C; Lea S; Booth G; Cadden P; Wreggett KA; Singh D
J Pharmacol Exp Ther; 2011 Sep; 338(3):732-40. PubMed ID: 21610141
[TBL] [Abstract][Full Text] [Related]
4. RV568, a narrow-spectrum kinase inhibitor with p38 MAPK-α and -γ selectivity, suppresses COPD inflammation.
Charron CE; Russell P; Ito K; Lea S; Kizawa Y; Brindley C; Singh D
Eur Respir J; 2017 Oct; 50(4):. PubMed ID: 29074542
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological profile of AW-814141, a novel, potent, selective and orally active inhibitor of p38 MAP kinase.
Chopra P; Kulkarni O; Gupta S; Bajpai M; Kanoje V; Banerjee M; Bansal V; Visaga S; Chatterjee M; Chaira T; Shirumalla RK; Verma AK; Dastidar SG; Sharma G; Ray A
Int Immunopharmacol; 2010 Apr; 10(4):467-73. PubMed ID: 20093202
[TBL] [Abstract][Full Text] [Related]
6. Anti-inflammatory effect and selectivity profile of AS1940477, a novel and potent p38 mitogen-activated protein kinase inhibitor.
Terajima M; Inoue T; Magari K; Yamazaki H; Higashi Y; Mizuhara H
Eur J Pharmacol; 2013 Jan; 698(1-3):455-62. PubMed ID: 23183108
[TBL] [Abstract][Full Text] [Related]
7. Pamapimod, a novel p38 mitogen-activated protein kinase inhibitor: preclinical analysis of efficacy and selectivity.
Hill RJ; Dabbagh K; Phippard D; Li C; Suttmann RT; Welch M; Papp E; Song KW; Chang KC; Leaffer D; Kim YN; Roberts RT; Zabka TS; Aud D; Dal Porto J; Manning AM; Peng SL; Goldstein DM; Wong BR
J Pharmacol Exp Ther; 2008 Dec; 327(3):610-9. PubMed ID: 18776065
[TBL] [Abstract][Full Text] [Related]
8. The development of AZD7624 for prevention of exacerbations in COPD: a randomized controlled trial.
Patel NR; Cunoosamy DM; Fagerås M; Taib Z; Asimus S; Hegelund-Myrbäck T; Lundin S; Pardali K; Kurian N; Ersdal E; Kristensson C; Korsback K; Palmér R; Brown MN; Greenaway S; Siew L; Clarke GW; Rennard SI; Make BJ; Wise RA; Jansson P
Int J Chron Obstruct Pulmon Dis; 2018; 13():1009-1019. PubMed ID: 29628759
[TBL] [Abstract][Full Text] [Related]
9. DBM1285 suppresses tumor necrosis factor alpha production by blocking p38 mitogen-activated protein kinase/mitogen-activated protein kinase-activated protein kinase 2 signaling pathway.
Kang JS; Kim HM; Choi IY; Han SB; Yoon YD; Lee H; Park KH; Cho IJ; Lee CW; Lee K; Lee KH; Park SK
J Pharmacol Exp Ther; 2010 Aug; 334(2):657-64. PubMed ID: 20427474
[TBL] [Abstract][Full Text] [Related]
10. Biological effects of p38 MAPK inhibitor losmapimod does not translate to clinical benefits in COPD.
Pascoe S; Costa M; Marks-Konczalik J; McKie E; Yang S; Scherbovsky PS
Respir Med; 2017 Sep; 130():20-26. PubMed ID: 29206629
[TBL] [Abstract][Full Text] [Related]
11. SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence.
Underwood DC; Osborn RR; Kotzer CJ; Adams JL; Lee JC; Webb EF; Carpenter DC; Bochnowicz S; Thomas HC; Hay DW; Griswold DE
J Pharmacol Exp Ther; 2000 Apr; 293(1):281-8. PubMed ID: 10734180
[TBL] [Abstract][Full Text] [Related]
12. Reversal of corticosteroid insensitivity by p38 MAPK inhibition in peripheral blood mononuclear cells from COPD.
Khorasani N; Baker J; Johnson M; Chung KF; Bhavsar PK
Int J Chron Obstruct Pulmon Dis; 2015; 10():283-91. PubMed ID: 25678784
[TBL] [Abstract][Full Text] [Related]
13. Cytokine regulation by MAPK activated kinase 2 in keratinocytes exposed to sulfur mustard.
Yego EC; Dillman JF
Toxicol In Vitro; 2013 Oct; 27(7):2067-75. PubMed ID: 23851002
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological effects of SB 220025, a selective inhibitor of P38 mitogen-activated protein kinase, in angiogenesis and chronic inflammatory disease models.
Jackson JR; Bolognese B; Hillegass L; Kassis S; Adams J; Griswold DE; Winkler JD
J Pharmacol Exp Ther; 1998 Feb; 284(2):687-92. PubMed ID: 9454815
[TBL] [Abstract][Full Text] [Related]
15. The p38 mitogen activated protein kinase inhibitor losmapimod in chronic obstructive pulmonary disease patients with systemic inflammation, stratified by fibrinogen: A randomised double-blind placebo-controlled trial.
Fisk M; Cheriyan J; Mohan D; Forman J; Mäki-Petäjä KM; McEniery CM; Fuld J; Rudd JHF; Hopkinson NS; Lomas DA; Cockcroft JR; Tal-Singer R; Polkey MI; Wilkinson IB
PLoS One; 2018; 13(3):e0194197. PubMed ID: 29566026
[TBL] [Abstract][Full Text] [Related]
16. Second-generation inhibitors demonstrate the involvement of p38 mitogen-activated protein kinase in post-transcriptional modulation of inflammatory mediator production in human and rodent airways.
Birrell MA; Wong S; McCluskie K; Catley MC; Hardaker EL; Haj-Yahia S; Belvisi MG
J Pharmacol Exp Ther; 2006 Mar; 316(3):1318-27. PubMed ID: 16368902
[TBL] [Abstract][Full Text] [Related]
17. Icariin inhibits TNF-α/IFN-γ induced inflammatory response via inhibition of the substance P and p38-MAPK signaling pathway in human keratinocytes.
Kong L; Liu J; Wang J; Luo Q; Zhang H; Liu B; Xu F; Pang Q; Liu Y; Dong J
Int Immunopharmacol; 2015 Dec; 29(2):401-407. PubMed ID: 26507164
[TBL] [Abstract][Full Text] [Related]
18. Role of inhibition of p38 mitogen-activated protein kinase in liver dysfunction after hemorrhagic shock and resuscitation.
Lv KY; Yu XY; Bai YS; Zhu SH; Tang HT; Ben DF; Xiao SC; Wang GY; Ma B; Xia ZF
J Surg Res; 2012 Dec; 178(2):827-32. PubMed ID: 22560853
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of the p38 MAPK inhibitor losmapimod for patients with chronic obstructive pulmonary disease: a randomised, double-blind, placebo-controlled trial.
Watz H; Barnacle H; Hartley BF; Chan R
Lancet Respir Med; 2014 Jan; 2(1):63-72. PubMed ID: 24461903
[TBL] [Abstract][Full Text] [Related]
20. A Randomized Dose-Escalation Study of the Safety and Anti-Inflammatory Activity of the p38 Mitogen-Activated Protein Kinase Inhibitor Dilmapimod in Severe Trauma Subjects at Risk for Acute Respiratory Distress Syndrome.
Christie JD; Vaslef S; Chang PK; May AK; Gunn SR; Yang S; Hardes K; Kahl L; Powley WM; Lipson DA; Bayliffe AI; Lazaar AL
Crit Care Med; 2015 Sep; 43(9):1859-69. PubMed ID: 26102252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
